Cost–consequence Analysis of Fluticasone Furoate/Vilanterol 92/22 MCG for the Management of COPD in the Spanish NHS

ClinicoEconomics and Outcomes Research- New Zealand

doi 10.2147/ceor.s169154

Full Text

Abstract

Available in

Date

Authors

Publisher

Informa UK Limited

Related search

Prs38 - Cost-Consequence Analysis of Fluticasone Furoate/Vilanterol for Asthma Management in Spain: An Analysis Based on the Salford Lung Study in Asthma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Prs48 - Cost – Effectiveness Analysis of Vilanterol/Fluticasone Furoate for Asthma Treatment in the Russian Federation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Reduction in All-Cause Mortality With Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2020English

A Comparison of the Efficacy and Safety of Once-Daily Fluticasone Furoate/Vilanterol With Twice-Daily Fluticasone Propionate/Salmeterol in Moderate to Very Severe COPD

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2013English

A Randomised Trial of Fluticasone Furoate/Vilanterol (50/25 Μg; 100/25 Μg) on Lung Function in COPD

Respiratory Medicine
PulmonaryRespiratory Medicine
2013English

Single-Inhaler Triple Therapy Utilizing the Once-Daily Combination of Fluticasone Furoate, Umeclidinium and Vilanterol in the Management of COPD: The Current Evidence Base and Future Prospects

Therapeutic Advances in Respiratory Disease
PulmonaryRespiratory MedicinePharmacology
2018English

Benefit and Safety of Fluticasone Furoate/Vilanterol in the Salford Lung Study in Chronic Obstructive Pulmonary Disease (SLS COPD) According to Baseline Patient Characteristics and Treatment Subgroups

Respiratory Medicine
PulmonaryRespiratory Medicine
2019English

Corrigendum to “Fluticasone Furoate/Vilanterol (100/25; 200/25 Μg) Improves Lung Function in COPD: A Randomised Trial” [Respir Med 107 (2013) 550–559]

Respiratory Medicine
PulmonaryRespiratory Medicine
2013English

Corrigendum to “A Randomised Trial of Fluticasone Furoate/Vilanterol (50/25 Μg; 100/25 Μg) on Lung Function in COPD” [Respir Med, 107 (2013) 560–569]

Respiratory Medicine
PulmonaryRespiratory Medicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy